)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Guerbet
Guerbet (GBT) investor relations material
Guerbet Q3 2026 TU earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2026 TU earnings summary22 Oct, 2026
Executive summary
9M 2026 revenue €573.8m, down 1.3% at CER and like-for-like; excluding China, revenue grew 1%, with positive contributions from EMEA, the Americas and Asia.
Q3 revenue fell 3.6% at CER and like-for-like, but was stable excluding China; all 2026 financial targets were confirmed.
Financial highlights
9M revenue was down 2.2% reported and 1.3% at CER; the €4.8m negative FX impact was confined to H1 and largely linked to yen depreciation.
Q3 revenue was €194.6m versus €198.7m in Q3 2025; like-for-like revenue fell 3.6% at CER.
Outlook and guidance
FY 2026 revenue target remains stable or showing a slight decrease at CER and like-for-like.
FY 2026 restated EBITDA margin target remains around 8%, including around €35m of Raleigh remediation-plan costs.
FY 2026 free cash flow target remains strongly negative at -€50m to -€70m, reflecting lower restated EBITDA, higher CAPEX and non-recurring restructuring costs.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Guerbet
- Near-flat H1 sales masked losses as refinancing and Raleigh recovery remained pivotal.GBT
H1 2026 - H1 2026 revenue stable at CER, with regional contrasts and ongoing transformation costs.GBTQ2 2026 TU
- Q1 2026 revenue grew 2.6% at CER, driven by EMEA and Asia, despite Raleigh site challenges.GBTQ1 2026 TU
- Net loss of €112.7m driven by impairment, with 2026 outlook negatively impacted by Raleigh.GBTH2 2025
- 2025 revenue fell 3.5% at CER, but EBITDA margin and cash flow outlooks remain positive.GBTQ4 2025 TU
- Q3 2025 marked a return to growth, led by Elucirem™ and LipiodolⓇ momentum.GBTQ3 2025 TU
- Revenue and profitability fell, prompting lower 2025 guidance and a focus on recovery.GBTH1 2025
- Revenue up 11.8% at CER, EBITDA margin 15.4%, net income €10m, 2024 outlook raised.GBTH1 2024
- Sales up 9% to €849m, margin above target, net income down, 2025 outlook positive.GBTH2 2024
Next Guerbet earnings date
Q4 2026 TU4 Feb, 2027
Guerbet
Next Guerbet earnings date
Q4 2026 TU4 Feb, 2027
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Guerbet SA is a France-based healthcare company specializing in the development, manufacture, and distribution of diagnostic imaging products, particularly contrast agents used in medical imaging. Guerbet offers a comprehensive range of imaging solutions for Computed Tomography (CT)/Cath Lab examinations, Magnetic Resonance Imaging (MRI), and interventional imaging. Their product lineup includes iodinated active ingredients for CT/Cath Lab contrast agents and gadolinium complexes for MRI. The company is headquartered in Villepinte, France, and its shares are listed on the Euronext Paris.